April 2021 Newsletter

Oklahoma Becomes Final State to Permit Biosimilar Substitution    On April 22nd, Oklahoma Governor Kevin Stitt signed SB 4, making Oklahoma the 50th and final state to enact a law permitting biosimilar substitution.   SB 4, like similar legislation in other states, permits interchangeable biosimilars to be substituted at the pharmacy level once approved by […]

Read More


March 2021 Newsletter

ASBM Leads Three Panel Discussions at Festival of Biologics USA 2021   From March 29th-31st ASBM representatives led three panel discussions at the World Biosimilar Congress USA 2021, part of the annual Festival of Biologics USA. Typically held in San Diego, CA, the event was conducted virtually this year due the COVID-19 pandemic.   On March 29th, […]

Read More


February 2020

Controversial Biosimilar Switching Policy in Canada in 2021    As of February, two Canadian provinces, British Columbia and Alberta, have implemented or partially implemented forced biosimilar non-medical switching policies. The controversial policies drew strong objections from many in the GI patient and physician community.   In a 2017 survey, more than 2/3 of Canadian physicians surveyed said […]

Read More


January 2020

ASBM’s Andrew Spiegel Interviewed on Susan G. Komen Podcast On January 28, the Susan G. Komen Foundation released an episode of their podcast “Real Pink” entitled  “The Evolution of Biosimilars as a Cancer Treatment” featuring Andrew Spiegel. Mr. Spiegel is Executive Director of the Global Colon Cancer Association and a founding member of ASBM.    In the […]

Read More


December 2020

ASBM Paper is GaBI Journal’s Most-Read Biosimilars Article of 2020 According to the editors of the Journal of the Generics and Biosimilar Initiative (GaBI Journal), the most-viewed biosimilars article of 2020 was the whitepaper “Policy recommendations for a sustainable biosimilars market: lessons from Europe”, co-authored by ASBM’s Executive Director Michael Reilly and Advisory Board Chair Philip Schneider. […]

Read More


November 2020

ASBM Presents to Saudi Gastroenterology Association On November 22nd and 29th, ASBM Executive Director Michael Reilly and Advisory Board Chair Philip Schneider presented to the Saudi Gastroenterology Association. The 45-minute presentation was livestreamed to gatherings of several hundred gastroenterologists in the three largest cities in Saudi Arabia: Riyadh, Jeddah, and Dammam. Entitled “Lessons from European Biosimilar […]

Read More


September 2020 Newsletter

Comment Period Open for MHRA Guidance on the Licensing of Biosimilar Products (UK)   The United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) has opened a six-week consultation period on new guidance intended to help developers of biosimilars more clearly understand the requirements for biosimilar products in the UK.   The new guidance is based on […]

Read More


October 2020

ASBM Launches New Microsite on Forced Switching in Canada On October 28th, ASBM launched a new microsite focused on the issue of forced biosimilar substitution in Canada- the forcing of patients off their physician-prescribed biologics and onto preferred government-chosen products.   www.NoForcedSwitching.ca   This controversial practice is rare among the advanced countries of the world, […]

Read More


July-August 2020 Newsletter

GaBI Publishes ASBM Whitepaper on European Physician Survey On August 28th, the Journal of the Generics and Biosimilars Initiative (GaBI Journal) published a whitepaper entitled “European prescribers’ attitudes and beliefs on biologicals prescribing and automatic substitution”. The paper explores in detail the findings of ASBM’s survey of 579 prescribers of biologic medicines from 10 practice areas in 6 Western […]

Read More


June 2020 Newsletter

Comment Period on NIOSH Hazardous Drugs List Extended to July 30th    The National Institute for Occupational Safety and Health (NIOSH) has extended the comment period regarding its proposed Hazardous Drugs List additions for 2020. The comments on the proposed list are now due July 30th. Several biologic medicines have been proposed- in ASBM’s view inappropriately- […]

Read More